H5N1 News and Research

Latest H5N1 News and Research

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

Generex Biotechnology Corporation today announced presentations in respect of the technologies and development products of its wholly-owned subsidiary, Antigen Express, Inc. The presentations were made at the conference Gene based Vaccines: Optimizing Development and Delivery 2010 held September 13 and 14, 2010 in Vienna, Austria and at the Immunotherapeutics and Vaccine Summit held in Cambridge, MA from August 17-19, 2010.

17 Sep 2010

CytoGenix reports positive results of CYDBA507 avian influenza vaccine candidate

CytoGenix reports positive results of an animal study where mice were immunized with CYDBA507, CytoGenix avian influenza vaccine candidate, protected against lethal challenge with avian influenza virus.

15 Sep 2010

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from the North Mississippi Health Services Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Sep 2010

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemopurifier® to capture immunosuppressive exosomes derived from individuals with metastatic melanoma.

9 Sep 2010

Research provides new framework for quantifying risk of avian-borne diseases

In 2005 an outbreak of the H5N1 'bird flu' virus in South East Asia led to widespread fear with predictions that the intercontinental migration of wild birds could lead to global pandemic.

4 Sep 2010

Medicago included in President's report that examines drugs to prevent spread of infectious diseases

Medicago Inc., a clinical-stage biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it was included in a report of President Obama's Council of Advisors on Science and Technology entitled "Report to the President on Reengineering the Influenza Vaccine Production Enterprise to Meet the Challenges of Pandemic Influenza", which was released earlier this month. U.S. Health and Human Services Secretary Kathleen Sebelius and other public health officials held a briefing to discuss this report and the $2 billion plan to accelerate the development of drugs and vaccines to prevent the spread of infectious diseases.

31 Aug 2010

Nanotherapeutics files NanoDTPA IND for treatment of radiation exposure

Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA™ an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid). DTPA is used to remove radioactive compounds from the body to help eliminate the contamination. The NanoDTPA™ capsule is a unique orally-bioavailable fine particle formulation that allows DTPA to be absorbed into the body from the gastrointestinal tract.

30 Aug 2010

Aethlon Medical receives approval for Chronic HCV Infection treatment

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled "Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy."

26 Aug 2010

Scientists identify compound to treat Chagas' disease

A new compound may offer an effective drug candidate against the deadly tropical infection, Chagas' disease say researchers from Brazil. They report their findings in the August 2010 issue of the journal Antimicrobial Agents and Chemotherapy.

21 Aug 2010

Intercell reports significant increase in second quarter revenue

Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets

17 Aug 2010

CEL-SCI Corporation third quarter 2010 net loss decreases to $0.6 million

CEL-SCI reported a net loss for the three months ended June 30, 2010 of ($0.6) million versus a loss of ($6.2) million during the same three months in fiscal year 2009. Net loss per basic share was ($0.00) for the three months ended June 30, 2010 versus a loss per basic share of ($0.05) during the same three months in fiscal year 2009. The loss during the quarter ended June 30, 2010 was reduced by a gain on derivative instruments of $2.75 million.

17 Aug 2010

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

NanoViricides, Inc., reports that its anti-Herpes drug candidates demonstrated significant efficacy in the recently completed cell culture studies. The studies were performed in the laboratory of Dr. Ken Rosenthal at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

16 Aug 2010

Sinovac Biotech second-quarter 2010 sales increase 131% to $10.3 million

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month and six-month periods ended June 30, 2010.

16 Aug 2010

Inovio Pharmaceuticals 2010 second quarter net loss decreases

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010.Total revenue was $1.1 million and $2.5 million for the three and six months ended June 30, 2010, compared to $2.5 million and $2.9 million for the three and six months ended June 30, 2009, respectively.

16 Aug 2010

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

Temasek Life Science Ventures Pte Ltd and Emergent BioSolutions Inc. today announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and commercialize a multivalent, cross-protective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains.

12 Aug 2010

Medicago USA awarded $21M to develop vaccine facility in Research Triangle Park

Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., a clinical-stage biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has been awarded a $21 Million grant from the Defense Advanced Research Projects Agency, Broad Agency Announcement, Defense Sciences Research & Technology to demonstrate the scalable manufacturing of its plant-expressed VLP vaccines in the U.S.A. under a Technology Investment Agreement.

11 Aug 2010

CEL-SCI produces and fills first lot of Multikine

CEL-SCI Corporation announced today that it has successfully produced and filled its first lot of Multikine® in preparation for the upcoming pivotal Phase III trial targeting advanced primary head and neck cancer.

5 Aug 2010

NanoViricides presents study results of nanoviricides anti-Ebola agents

NanoViricides, Inc. reports that the results of the evaluation of several of its nanoviricides anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."

20 Jul 2010

BioRadar develops TransFMDV for Foot and Mouth Disease

BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.

17 Jul 2010

Hemispherx publishes report of Japanese government funded program to develop nasally delivered H5N1 vaccine

Hemispherx Biopharma, Inc. announced that it was publicizing the full technical (unedited) report in Japanese, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease (NIID, formerly Japan's National Institute of Health) and the certified English translation.

16 Jul 2010

H5N1 News and Research

Latest H5N1 News and Research

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

CytoGenix reports positive results of CYDBA507 avian influenza vaccine candidate

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Research provides new framework for quantifying risk of avian-borne diseases

Medicago included in President's report that examines drugs to prevent spread of infectious diseases

Nanotherapeutics files NanoDTPA IND for treatment of radiation exposure

Aethlon Medical receives approval for Chronic HCV Infection treatment

Scientists identify compound to treat Chagas' disease

Intercell reports significant increase in second quarter revenue

CEL-SCI Corporation third quarter 2010 net loss decreases to $0.6 million

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

Sinovac Biotech second-quarter 2010 sales increase 131% to $10.3 million

Inovio Pharmaceuticals 2010 second quarter net loss decreases

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

Medicago USA awarded $21M to develop vaccine facility in Research Triangle Park

CEL-SCI produces and fills first lot of Multikine

NanoViricides presents study results of nanoviricides anti-Ebola agents

BioRadar develops TransFMDV for Foot and Mouth Disease

Hemispherx publishes report of Japanese government funded program to develop nasally delivered H5N1 vaccine

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

H5N1 News and Research

Latest H5N1 News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in